Search

Epcoritamab

Although this regimen is effective in up to 60% of patients, patients with relapsed or refractory DLBCL have poor outcomes. … Epcoritamab is an IgG1-bispecific antibody that simultaneously binds to CD3 on T-cells and CD20 on B-cells.

Entacapone

Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols.

Lumateperone

[A189093] It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology … [A189093,A189174] The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia.

Oxycodegol

Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain [L3263] … The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class [A33997, A34016].

Azficel-T

Azficel-T is marketed in the US as Laviv for intradermal injection. … Azficel-T is an autologous cellular product composed of fibroblasts indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.

Moxestrol

Fencamfamin

Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant. … Fencamfamin is used for treating depressive day-time fatigue, lack of concentration and lethargy. It is especially useful in patients with chronic conditions due to its favourable safety profile.

Alemtuzumab

The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). … Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin.[L43397] Alemtuzumab was approved by the FDA in 2001.

Lomitapide

[A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446] … [A275444, A7367] It was developed to address the significant unmet medical need in patients with homozygous familial hypercholesterolemia (HoFH)—an ultra-rare and life-threatening genetic disorder characterized

Ferric oxide

It is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, and iron(II,III) oxide (Fe3O4) which naturally as magnetite. … Iron(III) oxide or ferric oxide is the inorganic compound with the formula Fe2O3.